intralesional

Type: Keyphrase
Name: intralesional
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas

Data Presented at the European Society for Medical Oncology Congress in Spain Shows New Approach offers Overall Response Rate of 71% Contact InformationAvailable for logged-in reporters onlyCitationsEuropean Society for Medical OncologyNewswise — A formulation ... [Published Newswise - 4 hours ago]
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Medidata Appoints Mike Capone COO; PV-10 Data at Esmo 2014 Show

Below is a look at some of the headlines for companies that made news in the healthcare sector on September 29, 2014.Medidata (NASDAQ:MDSO) , the leading global provider of cloud-based solutions for clinical research in life sciences, announced Michael ... [Published BioMedReports - 22 hours ago]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ( http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment ... [Published Fort Mills Times - Sep 29 2014]
First reported Sep 23 2014 - Updated Sep 24 2014 - 9 reports

Provectus Biopharmaceuticals’ PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ( http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional ... [Published Fort Mills Times - Sep 24 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Intralesional Cryosurgery to Treat Keloid Scars: Results from a Retrospective Study

Background: A variety of treatment modalities have been proposed to treat keloid scars, but outcomes are often disappointing. Intralesional cryosurgery may significantly reduce these scars. Objective: To evaluate the clinical safety and efficacy of intralesional ... [Published Sexual Development - Sep 19 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Amgen applies for EU approval of new melanoma drug

:08 in Pharmaceutical Company Product News Amgen has applied for European Medicines Agency approval of an investigational oncolytic immunotherapy for the treatment of regionally or distantly metastatic melanoma. A marketing authorisation application has ... [Published Zenopa - Sep 08 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Amgen submits MAA to EMA for treatment of melanoma

(MarketLine via COMTEX News Network) -- Amgen Inc., a biotechnology company, has submitted a marketing authorization application, or MAA, to the European Medicines Agency, or EMA, via the centralized procedure for talimogene laherparepvec seeking approval ... [Published PredictWallStreet - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 1 reports

Amgen submits MAA for cancer immunotherapeutic

News EditorAmgen (NASDAQ:AMGN) submits a Marketing Authorization Application to the European Medicines Agency (EMA) for talimogene laherparepvec (TL) for the treatment of adult patients with melanoma that is regionally or distantly metastatic. TL is an ... [Published Seeking Alpha - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Surgery remains ‘gold standard’ for basal cell carcinoma

Surgery remains the ideal treatment for patients with basal cell carcinoma, according to results of an evidence review.Researchers with Columbia University Medical Center’s department of dermatology searched four databases — PubMed, Ovid MEDLINE, Cochrane ... [Published Orthopedics Today - Sep 01 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion

In multiple sclerosis (MS) occasionally acute lesions show a reduced apparent diffusion coefficient (ADC) on magnetic resonance imaging (MRI); however, the underlying mechanism of this phenomenon is not known. We compared cerebrospinal fluid (CSF) findings ... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of Keloid and Hypertrophic scars

AbstractObjective: To compare the use of intralesional triamcinolone acetonide and its combination with 5 flourouracil in the treatment of keloid and hypertrophic scars in terms of reduction in initial height of the scar.Methods: The randomised controlled ... [Published JPMA - Aug 25 2014]

Quotes

Eric Wachter, PhD and Chief Technology Officer of Provectus, said, "We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma.”"
...time for Medidata, with increasing acknowledgement of the Medidata Clinical Cloud™ as the life sciences' strongest cloud platform," said Sherif. "Mike's leadership in large-scale SaaS software development and his deep operational experience make him the right person to help us seize this moment and scale Medidata to capture the enormous opportunity ahead of us."
...pvct.com ), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal…"
...Dr Sean Harper, executive vice-president of research and development at Amgen, said: "The submission of the marketing authorisation application in Europe for talimogene laherparepvec brings us a step closer to helping address an unmet medical need for patients with metastatic melanoma."

More Content

All (23) | News (19) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Novel Rose Bengal Formulation Obliterates Lesio... [Published Newswise - 4 hours ago]
Medidata Appoints Mike Capone COO; PV-10 Data a... [Published BioMedReports - 22 hours ago]
Provectus Biopharmaceuticals Data Presented At ... [Published Fort Mills Times - Sep 29 2014]
Provectus Biopharmaceuticals’ PV-10 Clinical Da... [Published Fort Mills Times - Sep 24 2014]
Provectus Biopharmaceuticals’ PV-10 Clinical Da... [Published Fat Pitch Financials - Sep 24 2014]
Provectus Biopharmaceuticals’ PV-10 Clinical Da... [Published Wall Street Business Network - Sep 24 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Fort Mills Times - Sep 23 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Digital Journal - Sep 23 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published EON Science - Sep 23 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published WGNT - Sep 23 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Business Wire Science: Science News - Sep 23 2014]
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Business Wire Health News - Sep 23 2014]
Intralesional Cryosurgery to Treat Keloid Scars... [Published Sexual Development - Sep 19 2014]
Amgen applies for EU approval of new melanoma drug [Published Zenopa - Sep 08 2014]
Amgen submits MAA to EMA for treatment of melanoma [Published PredictWallStreet - Sep 05 2014]
Amgen submits talimogene laherparepvec's MAA fo... [Published Individual.com - Sep 03 2014]
Amgen files for EU approval of talimogene laher... [Published Pharma Letter - Sep 03 2014]
Amgen submits MAA for cancer immunotherapeutic [Published Seeking Alpha - Sep 02 2014]
Amgen Submits MAA In Europe For Talimogene Lahe... [Published RTTNews.com - Sep 02 2014]
Surgery remains ‘gold standard’ for basal cell ... [Published Orthopedics Today - Sep 01 2014]
Cerebrospinal fluid pleocytosis in multiple scl... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
Intralesional triamcinolone alone and in combin... [Published JPMA - Aug 25 2014]
Treatment of hepatitis C virus with telaprevir ... [Published PharmCast - Mar 19 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published EON Science - Sep 23 2014]
KNOXVILLE, Tenn.--(EON: Enhanced Online News)--PROVECTUS’ INTRALESIONAL PV-10 AND CO-INHIBITORY BLOCKADE DATA TO BE PRESENTED AT SITC 29TH ANNUAL MEETING Conference to be Held November 6-9, 2014 in National Harbor, MD. ...
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Business Wire Science: Science News - Sep 23 2014]
KNOXVILLE, Tenn.--(BUSINESS WIRE)--PROVECTUS’ INTRALESIONAL PV-10 AND CO-INHIBITORY BLOCKADE DATA TO BE PRESENTED AT SITC 29TH ANNUAL MEETING Conference to be Held November 6-9, 2014 in National Harbor, MD. ...
Provectus’ Intralesional Pv-10 and Co-Inhibitor... [Published Business Wire Health News - Sep 23 2014]
KNOXVILLE, Tenn.--(BUSINESS WIRE)--PROVECTUS’ INTRALESIONAL PV-10 AND CO-INHIBITORY BLOCKADE DATA TO BE PRESENTED AT SITC 29TH ANNUAL MEETING Conference to be Held November 6-9, 2014 in National Harbor, MD. ...
Cerebrospinal fluid pleocytosis in multiple scl... [Published Multiple Sclerosis Journal current issue - Aug 26 2014]
In multiple sclerosis (MS) occasionally acute lesions show a reduced apparent diffusion coefficient (ADC) on magnetic resonance imaging (MRI); however, the underlying mechanism of this phenomenon is not known. We compared cerebrospinal fluid (CSF) findings ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.